Earn up to 1 AMA PRA Category I Credit™

Statement of Purpose:
An estimated 18.2 million Americans have diabetes, including individuals who have been diagnosed (13 million) and those who are as yet undiagnosed (5.2 million). According to the CDC, approximately 33.8% of the population has impaired fasting glucose levels, 15.4% have impaired glucose tolerance, and 40.1% have prediabetes. Risk factors for diabetes include family history of diabetes, body mass index greater than 25 kg per m2, sedentary lifestyle, hypertension, dyslipidemia, history of gestational diabetes or large-for-gestational-age infant, and polycystic ovary syndrome.
Blacks, Latin Americans, Native Americans, and Asian-Pacific Islanders also are at increased risk for diabetes. Adherence to the published clinical guidelines for diabetes management can improve the quality of life for these patients, and improve their outcomes with fewer complications.

• With knowledge of the underlying pathophysiology of type 2 diabetes and the importance of insulin resistance as a risk factor for the development of cardiovascular disease, you will aggressively treat diabetic patients to achieve tight glycemic control as described by the present guidelines for managing diabetes.

Target Audience:

This activity was developed to provide the most pertinent information to family physicians, general practitioners, general internists, nurse practitioners and physician assistants. Along with all involved in the care of patients with hypertension.

Accreditation Statement:
Release Date: April 18, 2007
Valid for credit through April 18, 2008

ACCME: Antidote Education Company is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  Antidote designates this continuing medical education activity for a maximum of 1 AMA PRA Category I Credit™.

Faculty & Disclosures:

Michael O. Fleming, MD, FAAFP - Assistant Clinical Professor of Family Medicine and Comprehensive Care, LSU Health Science Center School of Medicine, Shreveport, LA; Assistant Clinical Professor of Family Medicine, Department of Family and Community Medicine, Tulane University Medical School, New Orleans, LA; Senior Medical Director, Antidote Education Company, Dallas, TX

Dr. Fleming disclosed no relevant financial relationships.

Richard E. Pratley, MD - Professor of Medicine & Director of Diabetes & Metabolism Translational Medicine Unit, The University of Vermont College of Medicine, Burlington, VT

Dr. Pratley disclosed that he has received honoraiam GlaxoSmithKline, Merck, Novartis, Sanofi-Aventis.

Disclaimer: The EB CME credit awarded for this activity was based on practice recommendations that were the most current with the strongest level of evidence available at the time this activity was approved. Since clinical research is ongoing, the American Academy of Family Physicians recommends that learners verify sources and review these and other recommendations prior to implementation into practice.